-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Emerging Growth Research Highlights Criticality of First Phosphate G7-Backed LFP Battery Onshoring Solution as Cleantech Sector Accelerates Post U.S. Midterms
-
Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2026
-
Sekur Private Data Ltd. Provides Update on Expected Closing of Non-Brokered Private Placement
-
iFabric Corp Announces Record Revenues for Q3 2026 and the Nine Months Ended September 30, 2026
-
RenX Enterprises Reports Record Third Quarter Revenue of $4.49 Million, Up 27.6% Year Over Year
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Hawai‘i Falls to North Dakota State, Bowl Hopes Dashed
-
Big Mamma Founder Tigrane Seydoux Brings Italian Restaurant Group to Florida
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
Exousia Pro Files Reg A.
ORLANDO, FLORIDA / ACCESS Newswire / June 25, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, has filed a Reg A (File # 024-12629).
Exousia Pro has filed a Reg A to raise money for the following:
Use of Proceeds for Assumed Percentage of Company Offered Shares Sold in This Offering | ||||||||||||||
25% | 50% | 75% | 100% | |||||||||||
Investigational New Drug trials | 500,000 | 1,000,000 | 1,500,000 | 2,000,000 | ||||||||||
New Product Development | 250,000 | 500,000 | 750,000 | 1,000,000 | ||||||||||
Acquisition | 250,000 | 500,000 | 1,000,000 | 1,500,000 | ||||||||||
Lab Equipment | 100,000 | 150,000 | 200,000 | 250,000 | ||||||||||
Marketing | 50,000 | 75,000 | 100,000 | 150,000 | ||||||||||
Working Capital | 85,000 | 260,000 | 200,000 | 85,000 | ||||||||||
Total | $ | 1,235,000 | $ | 2,485,000 | $ | 3,735,000 | $ | 4,985,000 | ||||||
We plan to use the bulk of the money to begin Glioblastoma IND trials, while we work on partnering with a large pharmaceutical company. Our Scientific Advisory Board ("SAB") has identified the first new product we plan to bring to market from mushroom exosomes. We have allocated funds for future acquisitions, which will be used to cover legal and accounting costs. As we continue to evolve, we will need to add or update our existing lab equipment. The marketing money will be used to market our various exosome products. We are assembling a marketing team with decades of experience in television, PR, and IR to effectively market the Company and its products. The Company operates very lean, and with sales projected this month and beyond, we allocated the smallest amount to working capital.
Matt Dwyer, our President, stated, "Exousia Pro can grow with funding; we can expand our studies, which could lead to further IND trials, but we do not have to do all these things at once and dilute the hell out of the Company's shareholders. As we plan future studies, we will determine our costs and allocate funds accordingly, allowing us to raise money as needed. We hope to be a model other companies will follow and show how a Reg A can be beneficial without being detrimental to the shareholders."
Exousia Pro intends to conduct its Reg A offering in a drastically different manner than the typical OTC company. Instead, the Company plans to stay true to the offering price of the Reg A, that is, no discounts, as it raises capital and executes its ambitious business plan, with the support of its investors. The Company has established an anticipated schedule for the use of funding, and it will raise funds as needed, in accordance with this schedule.
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
[email protected]
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
T.Perez--AT